If you have been reading about assay standardization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
== Biosynthesis == The DNA sequence of these transporters is transcribed in the nucleus of the cell by RNA polymerase and undergoes splicing and capping before it travels to the cytoplasm. In the cytoplasm, translation begins via a sequence in exon 2 of the mRNA. Subsequently, protein folding and packaging insert the transporter into the membrane. The protein has a signal recognition particle that is recognized as it leaves the ribosome. N-glycosylation at various sites on hPAT1 is necessary for its transport function. Three of its extracellular residues are glycosylated and determine transport efficacy.
== Pyrogen removal (depyrogenation) == Pyrogens can often be difficult to remove from solution due to the high variability of their molecular weight. Pyrogens are also relatively thermally stable and insensitive to pH changes. However, several removal techniques exist.
=== Post-Reynolds era and the "Slugging Seventies" (1961–1980) === John Coleman started his coaching career at Essendon in 1961, thus ending the Dick Reynolds era at the club. In the same year, Essendon finished the season mid-table, and supporters were not expecting too much for the following season. However, the club blitzed the opposition in 1962, losing only two matches and finishing top of the table. Both losses were to the previous year's grand finalists. The finals posed no problems for the resurgent Dons, easily accounting for Carlton in the season's climax, winning the 1962 Premiership by 32 points. This was a remarkable result for Coleman, who, in just his second season of coaching, claimed the ultimate prize in Australian football. As so often is the case after a flag, the following two years were below standard. A further premiership in 1965 (won from 4th position on the ladder) was also unexpected due to periods of poor form during the 1965 season. The Bombers were a different club when the finals came around, but some of the credit for the improvement was given to the influence of Brian Sampson and Ted Fordham during the finals. Coleman's time as coach turned out to be much like his playing career: highly successful but cut short when he had to stand down due to health problems in 1967. Only six years later, on the eve of the 1973 season, he died of a heart attack at just 44 years of age. Following Coleman's retirement, the club experienced tough times on and off the field.
=== Drug War Capitalism === In 2014, journalist Dawn Paley wrote Drug War Capitalism, a book that highlights how the war on drugs functions as a tool for the US to leverage control and power over Latin America. As she points out, the US has increasingly been able to militarise parts of Latin America as a pretext for fighting the war on drugs, when in reality this militarisation serves to oppress local communities and open new lands to extract the region's vast mineral and oil wealth. Increased paramilitary, private military, and national sector (police and military force) violence against local communities coincides with economically significant regions in countries like Colombia, such as areas either with vast mineral wealth or areas where oil pipelines run through. Paley points to major joint security initiatives involving the US and Latin American countries, such as Plan Colombia with Colombia, and the Mérida Initiative with Mexico, which both resulted in increased extraction of natural resources, increased militarisation, and a weakened justice system. This occurred whilst the plans' prohibitiotary aims, to combat drug trafficking levels and drug cartels, completely failed.
Sources: en.wikipedia.org
== Recognition == In 2002, Inc. magazine named Ranpak among the top 50 most innovative small companies of the year based on the number of patents awarded. In March 2021, Fast Company magazine named Ranpak one of year's top innovators in logistics "for replacing traditional shipping materials [like bubble wrap] with paper alternatives."
Recent research has linked the rise in opioid-overdose deaths among Black Americans to the lack of safety, security, stability, and survival in their communities. Those missing pieces in these communities can be linked to a host of things including exposure to structural racism, lack of access to resources, and widespread mistrust in the healthcare system. Structural racism continues to have a lasting impact on predominantly Black communities in the United States. Racial segregation is one of the main forms of structural racism that has been linked to the increase in opioid-overdose related deaths among non-Hispanic Black Americans. Racial segregation does not only impact access to social and economic resources. It also has an impact on public health and disrupts access to health care. The impact that racial segregation has health care spills over to the access of substance use services. This leads to Black Americans having a more difficult time when seeking treatment for opioid use. Structural racism has also led to the consistent misdirection of funds and the over-funding of criminal legal systems within predominantly non-Hispanic Black communities. Instead of funding being used to improve substance abuse treatment and prevention, funds have been used to criminalize drugs and impose harsh penalties on Black community members. The policies put in place years ago have led to stereotyping and fear within Black communities that prevents Black Americans from seeking substance abuse treatment.
=== Biohybrid hydrogel dressings === Hydrogels may be modified to incorporate metal cations (e.g. copper (II)), degradable linkers (e.g. dextran), and adhesive functional groups (e.g. RGD). Integrating biological derivatives into synthetic hydrogels allows producers to tailor binding affinities and specificity, mechanical properties, and stimuli-responsive properties.
=== Improvements in forensics === With the advent of and improvements to DNA testing/DNA profiling and other forensics technology, many cold cases are being re-opened and prosecuted. Police departments are opening cold case units whose job is to re-examine cold case files. DNA evidence helps in such cases but as in the case of fingerprints, it is of no value unless there is evidence on file to compare it to. However, to combat that issue, the FBI is switching from using the Integrated Automated Fingerprint Identification System (IAFIS) to using a newer technology called the Next Generation Identification (NGI). Other improvements in forensics lie in fields such as:
=== Museum conservation === Humidity and temperature control to prevent bacterial and fungal growth is a key part of museum conservation. There is increasing evidence that xerophilic moulds are more common in museums than is generally admitted, with destructive effects on their collections, and this may have been exacerbated by the inadvertent creation of a xerophile-friendly environment.
Sources: en.wikipedia.org
=== Hyperinsulinemic euglycemic clamp === The gold standard for investigating and quantifying insulin resistance is the "hyperinsulinemic euglycemic clamp," so-called because it measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia. It is a type of glucose clamp technique. The test is rarely performed in clinical care, but is used in medical research, for example, to assess the effects of different medications. The rate of glucose infusion commonly is referred to in diabetes literature as the GINF value. The procedure takes about two hours. Through a peripheral vein, insulin is infused at 10–120 mU per m2 per minute. In order to compensate for the insulin infusion, glucose 20% is infused to maintain blood sugar levels between 5 and 5.5 mmol/L. The rate of glucose infusion is determined by checking the blood sugar levels every five to ten minutes. The insulin sensitivity is determined by the rate of glucose infusion during the last thirty minutes of the test. If high levels (7.5 mg/min or higher) are needed, the patient is considered insulin-sensitive. Conversely, very low levels (4.0 mg/min or lower) indicate insulin resistance. Levels falling between 4.0 and 7.5 mg/min are not conclusive and suggest "impaired glucose tolerance," which is an early indication of insulin resistance. This fundamental technique can be greatly enhanced through the utilization of glucose tracers. Glucose can be labeled with either stable or radioactive atoms.
== Bibliography == Denise Y. Arnold, Christine A. Hastorf (2008). Heads of State: Icons, Power, and Politics in The Ancient and Modern Andes. Left Coast Press. ISBN 9781598741711. Terence N. D'Altroy (1992). Provincial Power in The Inca Empire. Smithsonian Institution Press. ISBN 9781560981152. Terence N. D'Altroy (2003). The Incas. Wiley-Blackwell. ISBN 1-4051-1676-5. Teofilo Laime Ajacopa (2007), Diccionario Bilingue Iskay Simipi Yuyayk'ancha, La Paz. (Quechua-Spanish Dictionary) Terry V. LeVine, Ed. (1992), Inca Storage Systems, University of Oklahoma Press, ISBN 0-8061-2440-7. Timothy Parsons (2010). The Rule of Empires: Those Who Built Them, Those Who Endured Them, and Why They Always Fall. Oxford University Press. ISBN 9780199746194
Turosteride (FCE-26,073) is a selective inhibitor of the enzyme 5α-reductase which was under investigation by GlaxoSmithKline for the treatment of benign prostatic hyperplasia (BPH), but was never marketed. Similarly to finasteride, turosteride is selective for the type II isoform of 5α-redcutase, with about 15-fold selectivity for it over type I isoform of the enzyme. In animal studies it has been shown to inhibit prostate size and retard tumor growth. It may also be useful for the treatment of acne and hair loss.
==== Leukemia ==== The Gβγ subunit has been shown to activate a Rho guanine nucleotide exchange factor (RhoGef) gene PLEKHG2 which is upregulated in a number of leukemia cell lines and mouse models of leukemia. Lymphocyte chemotaxis as a result of Rac and CDC42 activation as well as actin polymerization is believed to be regulated by the Gβγ activated RhoGef. Therefore, a drug inhibiting the Gβγ could play a role in the treatment of leukemia.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.